Prognostic Application 0f BRAF V600E in Papillary Thyroid Carcinoma: an Immunohistochemical Study
Conclusion This finding needs to be approved by molecular approaches, so we compared our results with previous IHC and molecular studies in Iraq and other countries. BRAFV600E IHC can be used as an alternative to molecular biology for the detection of mutations in patients with thyroid neoplasm.The BRAF V600E IHC mutation is strongly associated with the female than male gender, but it was not statistically significant. Also, BRAF V600E showed a negative relationship with age, tumor size, and lymph node metastasis. However, there was a strong correlation with pathological variables such as tumor focality, capsular invasion, and extra thyroid extension.The BRAF V600E IHC is regarded as a diagnostic and prognostic marker involved in malignant neoplasms especially with papillary thyroid carcinoma, which has a higher mutation rate.